2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

Overview

Journal Oncol Res

Specialty Oncology

Date 2016 May 15

PMID 27178822

Citations 14

Authors

Arya Sobhakumari

Kevin P Orcutt

Laurie Love-Homan

Christopher E Kowalski

Arlene D Parsons

C Michael Knudson

Andrean L Simons

Affiliations

Soon will be listed here.

Abstract

Poor tumor response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is a significant challenge for effective treatment of head and neck squamous cell carcinoma (HNSCC). Therefore, strategies that may increase tumor response to EGFR TKIs are warranted in order to improve HNSCC patient treatment and overall survival. HNSCC tumors are highly glycolytic, and increased EGFR signaling has been found to promote glucose metabolism through various mechanisms. We have previously shown that inhibition of glycolysis with 2-deoxy-d-glucose (2DG) significantly enhanced the antitumor effects of cisplatin and radiation, which are commonly used to treat HNSCC. The goal of the current studies is to determine if 2DG will enhance the antitumor activity of the EGFR TKI erlotinib in HNSCC. Erlotinib transiently suppressed glucose consumption accompanied by alterations in pyruvate kinase M2 (PKM2) expression. 2DG enhanced the cytotoxic effect of erlotinib in vitro but reversed the antitumor effect of erlotinib in vivo. 2DG altered the N-glycosylation status of EGFR and induced the endoplasmic reticulum (ER) stress markers CHOP and BiP in vitro. Additionally, the effects of 2DG + erlotinib on cytotoxicity and ER stress in vitro were reversed by mannose but not glucose or antioxidant enzymes. Lastly, the protective effect of 2DG on erlotinib-induced cytotoxicity in vivo was reversed by chloroquine. Altogether, 2DG suppressed the antitumor efficacy of erlotinib in a HNSCC xenograft mouse model, which may be due to increased cytoprotective autophagy mediated by ER stress activation.

Citing Articles

Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment.

Kleszcz R Cancers (Basel). 2023; 15(17).

PMID: 37686523 PMC: 10486994. DOI: 10.3390/cancers15174247.

Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism.

Bian C, Zheng Z, Su J, Wang H, Chang S, Xin Y Antioxidants (Basel). 2022; 11(11).

PMID: 36358574 PMC: 9686736. DOI: 10.3390/antiox11112202.

The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells.

Kleszcz R, Paluszczak J Int J Mol Sci. 2022; 23(3).

PMID: 35163171 PMC: 8835497. DOI: 10.3390/ijms23031248.

Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment.

Bao L, Xu T, Lu X, Huang P, Pan Z, Ge M Front Oncol. 2021; 11:773028.

PMID: 34926283 PMC: 8674491. DOI: 10.3389/fonc.2021.773028.

Laminar Flow on Endothelial Cells Suppresses eNOS O-GlcNAcylation to Promote eNOS Activity.

Basehore S, Bohlman S, Weber C, Swaminathan S, Zhang Y, Jang C Circ Res. 2021; 129(11):1054-1066.

PMID: 34605247 PMC: 8653916. DOI: 10.1161/CIRCRESAHA.121.318982.

References

Simons A, Fath M, Mattson D, Smith B, Walsh S, Graham M . Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys. 2007; 69(4):1222-30. PMC: 2267859. DOI: 10.1016/j.ijrobp.2007.07.2343. View

Schiavi A, Maglioni S, Palikaras K, Shaik A, Strappazzon F, Brinkmann V . Iron-Starvation-Induced Mitophagy Mediates Lifespan Extension upon Mitochondrial Stress in C. elegans. Curr Biol. 2015; 25(14):1810-22. DOI: 10.1016/j.cub.2015.05.059. View

Ling Y, Li T, Perez-Soler R, Haigentz Jr M . Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol. 2009; 64(3):539-48. DOI: 10.1007/s00280-008-0902-8. View

Weichselbaum R, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J . Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A. 1986; 83(8):2684-8. PMC: 323364. DOI: 10.1073/pnas.83.8.2684. View

Coleman M, Asbury C, Daniels D, Du J, Aykin-Burns N, Smith B . 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med. 2008; 44(3):322-31. DOI: 10.1016/j.freeradbiomed.2007.08.032. View

Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X . 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol. 2010; 67(4):899-910. PMC: 3093301. DOI: 10.1007/s00280-010-1391-0. View

Sequist L, Bell D, Lynch T, Haber D . Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007; 25(5):587-95. DOI: 10.1200/JCO.2006.07.3585. View

Sandulache V, Ow T, Pickering C, Frederick M, Zhou G, Fokt I . Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011; 117(13):2926-38. PMC: 3135768. DOI: 10.1002/cncr.25868. View

Rutkowski D, Kaufman R . A trip to the ER: coping with stress. Trends Cell Biol. 2004; 14(1):20-8. DOI: 10.1016/j.tcb.2003.11.001. View

10.

Fernandes H, Cohen S, Bishayee S . Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem. 2000; 276(7):5375-83. DOI: 10.1074/jbc.M005599200. View

11.

Weihua Z, Tsan R, Huang W, Wu Q, Chiu C, Fidler I . Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008; 13(5):385-93. PMC: 2413063. DOI: 10.1016/j.ccr.2008.03.015. View

12.

Guan X, Qian Y, Shen Y, Zhang L, Du Y, Dai H . Autophagy protects renal tubular cells against ischemia / reperfusion injury in a time-dependent manner. Cell Physiol Biochem. 2015; 36(1):285-98. DOI: 10.1159/000374071. View

13.

Yong Jeon J, Kim S, Park K, Yun M . The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. BMC Cancer. 2015; 15:623. PMC: 4562121. DOI: 10.1186/s12885-015-1640-z. View

14.

Ren J, Bollu L, Su F, Gao G, Xu L, Huang W . EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate. 2013; 73(13):1453-61. DOI: 10.1002/pros.22692. View

15.

Kim S, Yun M, Hong Y, Solca F, Kim J, Kim H . Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Ther. 2013; 12(10):2145-56. DOI: 10.1158/1535-7163.MCT-12-1188. View

16.

Shen Y, Yang J, Zhao J, Xiao C, Xu C, Xiang Y . The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: A survival mechanism in methotrexate-resistant choriocarcinoma cells. Exp Cell Res. 2015; 334(2):207-18. DOI: 10.1016/j.yexcr.2015.04.010. View

17.

Demaria M, Giorgi C, Lebiedzinska M, Esposito G, DAngeli L, Bartoli A . A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY). 2010; 2(11):823-42. PMC: 3006025. DOI: 10.18632/aging.100232. View

18.

Simons A, Ahmad I, Mattson D, Dornfeld K, Spitz D . 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007; 67(7):3364-70. PMC: 3852417. DOI: 10.1158/0008-5472.CAN-06-3717. View

19.

Kim S, Park H, Jeong H, Kim M, Kim M, Bae O . Autophagy sustains the survival of human pancreatic cancer PANC-1 cells under extreme nutrient deprivation conditions. Biochem Biophys Res Commun. 2015; 463(3):205-10. DOI: 10.1016/j.bbrc.2015.05.022. View

20.

Hidalgo M, Siu L, Nemunaitis J, Rizzo J, Hammond L, Takimoto C . Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19(13):3267-79. DOI: 10.1200/JCO.2001.19.13.3267. View